CA2320431A1 - Targeting of genetic vaccine vectors - Google Patents
Targeting of genetic vaccine vectors Download PDFInfo
- Publication number
- CA2320431A1 CA2320431A1 CA002320431A CA2320431A CA2320431A1 CA 2320431 A1 CA2320431 A1 CA 2320431A1 CA 002320431 A CA002320431 A CA 002320431A CA 2320431 A CA2320431 A CA 2320431A CA 2320431 A1 CA2320431 A1 CA 2320431A1
- Authority
- CA
- Canada
- Prior art keywords
- recombinant
- cells
- cell
- library
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002068 genetic effect Effects 0.000 title claims abstract description 167
- 229960005486 vaccine Drugs 0.000 title claims abstract description 142
- 239000013598 vector Substances 0.000 title claims description 231
- 230000008685 targeting Effects 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 211
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 68
- 230000001965 increasing effect Effects 0.000 claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims description 404
- 150000007523 nucleic acids Chemical class 0.000 claims description 148
- 108090000623 proteins and genes Proteins 0.000 claims description 146
- 102000039446 nucleic acids Human genes 0.000 claims description 142
- 108020004707 nucleic acids Proteins 0.000 claims description 142
- 230000027455 binding Effects 0.000 claims description 128
- 238000009739 binding Methods 0.000 claims description 128
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 109
- 108091007433 antigens Proteins 0.000 claims description 106
- 102000036639 antigens Human genes 0.000 claims description 105
- 229920001184 polypeptide Polymers 0.000 claims description 105
- 239000000427 antigen Substances 0.000 claims description 103
- 108091033319 polynucleotide Proteins 0.000 claims description 89
- 102000040430 polynucleotide Human genes 0.000 claims description 89
- 239000002157 polynucleotide Substances 0.000 claims description 89
- 102000004169 proteins and genes Human genes 0.000 claims description 74
- 238000012216 screening Methods 0.000 claims description 62
- 230000006798 recombination Effects 0.000 claims description 56
- 238000005215 recombination Methods 0.000 claims description 56
- 210000001519 tissue Anatomy 0.000 claims description 51
- 230000014509 gene expression Effects 0.000 claims description 43
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 38
- 231100000655 enterotoxin Toxicity 0.000 claims description 37
- 239000000147 enterotoxin Substances 0.000 claims description 36
- 241001515965 unidentified phage Species 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 30
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 27
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 26
- 230000009870 specific binding Effects 0.000 claims description 26
- 102000005962 receptors Human genes 0.000 claims description 25
- 108020003175 receptors Proteins 0.000 claims description 25
- 238000001727 in vivo Methods 0.000 claims description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 210000004443 dendritic cell Anatomy 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 108091007494 Nucleic acid- binding domains Proteins 0.000 claims description 22
- 101710146739 Enterotoxin Proteins 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 18
- 101710198693 Invasin Proteins 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- 210000003491 skin Anatomy 0.000 claims description 12
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 11
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- 230000004568 DNA-binding Effects 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 108010033040 Histones Proteins 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 210000001821 langerhans cell Anatomy 0.000 claims description 8
- 210000000663 muscle cell Anatomy 0.000 claims description 8
- 241000607626 Vibrio cholerae Species 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 230000030741 antigen processing and presentation Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 210000002510 keratinocyte Anatomy 0.000 claims description 5
- 230000002934 lysing effect Effects 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 230000016396 cytokine production Effects 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 230000001926 lymphatic effect Effects 0.000 claims description 4
- 210000003126 m-cell Anatomy 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 230000004543 DNA replication Effects 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 229940027941 immunoglobulin g Drugs 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229940124856 vaccine component Drugs 0.000 claims 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims 1
- 230000004570 RNA-binding Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 13
- 108020004414 DNA Proteins 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 61
- 239000003981 vehicle Substances 0.000 description 42
- 230000001976 improved effect Effects 0.000 description 34
- 239000000203 mixture Substances 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 23
- 150000001413 amino acids Chemical group 0.000 description 21
- 230000028993 immune response Effects 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 239000003053 toxin Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 108700012359 toxins Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 150000007513 acids Chemical class 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 102000009016 Cholera Toxin Human genes 0.000 description 10
- 108010049048 Cholera Toxin Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 102000044158 nucleic acid binding protein Human genes 0.000 description 9
- 108700020942 nucleic acid binding protein Proteins 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 108010055409 ganglioside receptor Proteins 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 238000002823 phage display Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 108010041986 DNA Vaccines Proteins 0.000 description 7
- 229940021995 DNA vaccine Drugs 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 101710096438 DNA-binding protein Proteins 0.000 description 6
- 208000014197 Fetal anticonvulsant syndrome Diseases 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- -1 interfemns Proteins 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 231100000617 superantigen Toxicity 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 208000003028 Stuttering Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000013602 bacteriophage vector Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000011239 genetic vaccination Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 102000047918 Myelin Basic Human genes 0.000 description 4
- 101710107068 Myelin basic protein Proteins 0.000 description 4
- 101710160107 Outer membrane protein A Proteins 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 1
- 101150025032 13 gene Proteins 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101100029932 Drosophila melanogaster lama gene Proteins 0.000 description 1
- 108700028018 Drosophila prd Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100127662 Mus musculus Lama1 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000701980 Phage 434 Species 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000701835 Salmonella virus P22 Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010068068 Transcription Factor TFIIIA Proteins 0.000 description 1
- 102100028509 Transcription factor IIIA Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055691 human APC Human genes 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011527 multiparameter analysis Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Substances [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2176998A | 1998-02-11 | 1998-02-11 | |
US7429498P | 1998-02-11 | 1998-02-11 | |
US09/021,769 | 1998-02-11 | ||
US60/074,294 | 1998-02-11 | ||
PCT/US1999/003023 WO1999041402A2 (en) | 1998-02-11 | 1999-02-10 | Targeting of genetic vaccine vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2320431A1 true CA2320431A1 (en) | 1999-08-19 |
Family
ID=26695070
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002320431A Abandoned CA2320431A1 (en) | 1998-02-11 | 1999-02-10 | Targeting of genetic vaccine vectors |
CA002320960A Abandoned CA2320960A1 (en) | 1998-02-11 | 1999-02-10 | Optimization of immunomodulatory properties of genetic vaccines |
CA002320626A Abandoned CA2320626A1 (en) | 1998-02-11 | 1999-02-10 | Genetic vaccine vector engineering |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002320960A Abandoned CA2320960A1 (en) | 1998-02-11 | 1999-02-10 | Optimization of immunomodulatory properties of genetic vaccines |
CA002320626A Abandoned CA2320626A1 (en) | 1998-02-11 | 1999-02-10 | Genetic vaccine vector engineering |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP1053312A2 (ja) |
JP (3) | JP2002503461A (ja) |
AU (3) | AU3291099A (ja) |
CA (3) | CA2320431A1 (ja) |
MX (3) | MXPA00007891A (ja) |
WO (3) | WO1999041369A2 (ja) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
EP1690868A1 (en) | 1997-10-31 | 2006-08-16 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
IL140125A0 (en) | 1998-06-17 | 2002-02-10 | Maxygen Inc | Method for producing polynucleotides with desired properties |
EP1104459A1 (en) | 1998-08-12 | 2001-06-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
CA2345203A1 (en) | 1998-10-07 | 2000-04-13 | Maxygen Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
AU1619400A (en) | 1998-11-10 | 2000-05-29 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
EP1072010B1 (en) | 1999-01-19 | 2010-04-21 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
MXPA00009723A (es) * | 1999-02-04 | 2003-09-22 | Diversa Corp | Generacion no estocastica de vacunas y enzimas geneticas. |
KR20010102069A (ko) | 1999-02-11 | 2001-11-15 | 추후제출 | 고효율 질량 분석 |
US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
WO2001007575A2 (en) | 1999-07-22 | 2001-02-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions |
AU5928400A (en) | 1999-07-22 | 2001-02-13 | Procter & Gamble Company, The | Protease conjugates having sterically protected clip sites |
CA2376045A1 (en) | 1999-07-22 | 2001-02-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
WO2001059071A2 (en) | 2000-02-09 | 2001-08-16 | Genvec, Inc. | Methods of preparing and using a viral vector library |
AU2001259957B2 (en) * | 2000-05-26 | 2006-06-15 | Savine Therapeutics Pty Ltd | Synthetic peptides and uses therefore |
AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
CA2411828A1 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
WO2002000897A2 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel chimeric promoters |
WO2002000232A2 (en) * | 2000-06-26 | 2002-01-03 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
US6858422B2 (en) | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
AU2004260931B9 (en) | 2003-04-29 | 2012-01-19 | E.I. Du Pont De Nemours And Company | Novel glyphosate-N-acetyltransferase (GAT) genes |
DE10060959A1 (de) * | 2000-12-06 | 2002-06-20 | Aventis Res & Tech Gmbh & Co | Verfahren zur Isolierung und Identifizierung von Effektoren |
US20020146732A1 (en) * | 2001-02-02 | 2002-10-10 | Padgett Hal S. | Method of increasing complementarity in a heteroduplex |
US6723537B2 (en) | 2001-05-18 | 2004-04-20 | Rigel Pharmaceuticals, Incorporated | Directed evolution of protein in mammalian cells |
AU2002326437A1 (en) * | 2001-07-19 | 2003-03-03 | Icogen Corporation | Methods for the identification of peptidyl compounds interacting with extracellular target molecules |
IL162077A0 (en) * | 2001-11-21 | 2005-11-20 | Univ Leland Stanford Junior | Polynucleotide therapy the board of trustees of the leland stanford junior university |
EP1572941A4 (en) | 2002-02-26 | 2009-03-18 | Maxygen Inc | NEW FLAVIVIRUS ANTIGENES |
US7783428B2 (en) | 2002-03-01 | 2010-08-24 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
US7620500B2 (en) | 2002-03-09 | 2009-11-17 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
CA2481411C (en) | 2002-04-19 | 2016-06-14 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
MXPA05001287A (es) | 2002-08-06 | 2005-08-03 | Verdia Llc | Variantes de amino oxidasa ap1. |
US8663622B2 (en) | 2002-12-16 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant vaccine viruses expressing IL-15 and methods using the same |
CA2920416A1 (en) | 2003-03-06 | 2004-10-28 | Basf Enzymes Llc | Amylases, nucleic acids encoding them and methods for making and using them |
CA2515583C (en) | 2003-03-07 | 2015-07-14 | Diversa Corporation | Hydrolases, nucleic acids encoding them and methods for making and using them |
ES2598037T3 (es) | 2003-04-04 | 2017-01-24 | Basf Enzymes Llc | Pectato liasas, ácidos nucleicos que las codifican y métodos para su preparación y uso |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
ES2401795T3 (es) | 2003-07-02 | 2013-04-24 | Syngenta Participations Ag | Glucanasas, ácidos nucleicos que las codifican y métodos para eleborarlas y utilizarlas |
EP1668113B1 (en) | 2003-08-11 | 2013-06-19 | Verenium Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
CA2735315A1 (en) | 2004-06-09 | 2005-12-29 | Pioneer Hi-Bred International, Inc. | Plastid transit peptides |
JP2008505619A (ja) | 2004-06-16 | 2008-02-28 | ヴェレニウム コーポレイション | 葉緑素を酵素的に脱色するための組成物及び方法 |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
US8426184B2 (en) | 2005-03-15 | 2013-04-23 | Bp Corporation North America | Cellulases, nucleic acids encoding them and methods for making and using them |
US8715988B2 (en) | 2005-03-28 | 2014-05-06 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
EP2216403A3 (en) | 2006-02-02 | 2010-11-24 | Verenium Corporation | Esterases and related nucleic acids and methods |
EP2420570B1 (en) | 2006-02-10 | 2013-12-04 | Verenium Corporation | Arabinofuranosidase enzymes, nucleic acids encoding them and methods for making and using them |
EP3406621A1 (en) | 2006-02-14 | 2018-11-28 | BP Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
JP5441417B2 (ja) | 2006-03-07 | 2014-03-12 | カーギル・インコーポレイテッド | アルドース、それをコードする核酸、ならびにそれを生成および使用する方法 |
ES2383767T3 (es) | 2006-03-07 | 2012-06-26 | Verenium Corporation | Aldolasas, ácidos nucleicos que las codifican y métodos para producir y usar las mismas |
CN106222185B (zh) | 2006-08-04 | 2021-12-03 | 维莱尼姆公司 | 葡聚糖酶、编码它们的核酸及制备和使用它们的方法 |
EP2617814B1 (en) | 2006-09-21 | 2015-11-18 | BASF Enzymes LLC | Phytases, nucleic acids encoding them and methods for making and using them |
MX2009003034A (es) | 2006-09-21 | 2009-11-18 | Verenium Corp | Fosfolipasas, acidos nucleicos que las codifican, y metodos de hacerlas y usarlas. |
BRPI0719449A2 (pt) | 2006-12-21 | 2017-06-20 | Syngenta Participations Ag | molécula de ácido nucléico isolada, sintética ou recombinante, polipeptídeo isolado, planta ou parte de planta, eículo de clonagem que compreende um ácido nucléico, cassete de expressão que compreende uma molécula de ácido nucléico e método para hidrolisar um polissacarídeo, oligossacarídeo ou amido |
AR065544A1 (es) | 2007-01-30 | 2009-06-17 | Verenium Corp | Enzimas para el tratamiento de lignocelulosicos acidos nucleicos que las codifican y metodos para prepararlas y usarlas |
EP2708602B1 (en) | 2007-10-03 | 2019-02-27 | BP Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
WO2009058564A2 (en) | 2007-11-01 | 2009-05-07 | Maxygen, Inc. | Immunosuppressive polypeptides and nucleic acids |
AU2008347234B2 (en) | 2008-01-03 | 2015-05-28 | Basf Enzymes Llc | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
WO2009088753A1 (en) | 2008-01-03 | 2009-07-16 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
CA2990650C (en) | 2008-05-23 | 2021-02-09 | Pioneer Hi-Bred International, Inc. | Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
ES2706899T3 (es) | 2008-09-26 | 2019-04-01 | Tocagen Inc | Vectores de terapia génica y citosina desaminasas |
AU2010249500B2 (en) | 2009-05-21 | 2016-03-24 | Basf Enzymes Llc | Phytases, nucleic acids encoding them and methods for making and using them |
US8592649B2 (en) | 2009-08-20 | 2013-11-26 | Pioneer Hi Bred International Inc | Functional expression of shuffled yeast nitrate transporter (YNT1) in maize to improve nitrate uptake under low nitrate environment |
UA109884C2 (uk) | 2009-10-16 | 2015-10-26 | Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування | |
UA111708C2 (uk) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | Спосіб рафінування олії |
WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
US8993837B2 (en) | 2010-08-13 | 2015-03-31 | Pioneer Hi-Bred International, Inc | Chimeric promoters and methods of use |
BR112014027468A2 (pt) | 2012-05-04 | 2017-06-27 | Du Pont | polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo. |
BR112015023286A2 (pt) | 2013-03-14 | 2018-03-06 | Arzeda Corp | polipeptídeo recombinante com atividade da dicamba descarboxilase, construto de polinucleotídeo, célula, método de produção de uma célula hospedeira compreendendo um polinucleotídeo heterólogo que codifica um polipeptídeo tendo atividade da dicamba descarboxilase, método para descarboxilar dicamba, um derivado de dicamba ou um metabolito de dicamba, método para a detecção de um polipeptideo e método para a detecção da presença de um polinucleotideo que codifica um polipeptideo tendo atividade da dicamba descarboxilase |
US20140289906A1 (en) | 2013-03-14 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Compositions Having Dicamba Decarboxylase Activity and Methods of Use |
CA2901316A1 (en) | 2013-03-15 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Phi-4 polypeptides and methods for their use |
WO2015023846A2 (en) | 2013-08-16 | 2015-02-19 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
ES2937045T3 (es) | 2013-09-13 | 2023-03-23 | Pioneer Hi Bred Int | Proteínas insecticidas y métodos para su uso |
WO2015120270A1 (en) | 2014-02-07 | 2015-08-13 | Pioneer Hi Bred International, Inc. | Insecticidal proteins and methods for their use |
MX2016010187A (es) | 2014-02-07 | 2017-07-11 | Pioneer Hi Bred Int | Proteinas insecticidas y metodos para su uso. |
KR102532832B1 (ko) * | 2014-09-11 | 2023-05-16 | 브이엘피 테라퓨틱스 인코포레이티드 | 플라비바이러스 바이러스 유사 입자 |
BR112017007932A2 (pt) | 2014-10-16 | 2018-01-23 | Du Pont | proteínas inseticidas e métodos para uso das mesmas |
CA2977026A1 (en) | 2015-03-11 | 2016-09-15 | E.I. Du Pont De Nemours And Company | Insecticidal combinations of pip-72 and methods of use |
CN116333064A (zh) | 2015-05-19 | 2023-06-27 | 先锋国际良种公司 | 杀昆虫蛋白及其使用方法 |
EP3943602A1 (en) | 2015-08-06 | 2022-01-26 | Pioneer Hi-Bred International, Inc. | Plant derived insecticidal proteins and methods for their use |
US20180325119A1 (en) | 2015-12-18 | 2018-11-15 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EP3960863A1 (en) | 2016-05-04 | 2022-03-02 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
MX2018015540A (es) * | 2016-06-20 | 2019-04-11 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado. |
MX2018015906A (es) | 2016-07-01 | 2019-04-04 | Pioneer Hi Bred Int | Proteinas insecticidas de plantas y metodos para sus usos. |
EP3535285B1 (en) | 2016-11-01 | 2022-04-06 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
CN110088123B (zh) | 2016-12-14 | 2023-10-20 | 先锋国际良种公司 | 杀昆虫蛋白及其使用方法 |
US11213028B2 (en) | 2016-12-22 | 2022-01-04 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
MX2019009371A (es) | 2017-02-08 | 2019-09-23 | Pionner Hi Bred Int Inc | Combinaciones insecticidas de proteinas insecticidas derivadas de plantas y metodos para su uso. |
MX2019013321A (es) | 2017-05-11 | 2020-02-10 | Pioneer Hi Bred Int | Proteinas insecticidas y metodos para su uso. |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
US20230235352A1 (en) | 2020-07-14 | 2023-07-27 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882278A (en) * | 1983-04-29 | 1989-11-21 | President And Fellows Of Harvard College | Non-toxinogenic vibrio cholerae mutants |
IL96475A0 (en) * | 1989-11-29 | 1991-08-16 | Innovative Tech Center | Chimeric proteins |
NZ265818A (en) * | 1993-04-19 | 1997-09-22 | Medisorb Technologies Internat | Compositions of nucleic acids encapsulated with molecules that facilitate uptake and integration into living cells |
SG54115A1 (en) * | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
WO1994026787A1 (en) * | 1993-05-07 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for generating cell type specific phage antibody libraries |
SE9304060D0 (sv) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
AU712714B2 (en) * | 1994-10-03 | 1999-11-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system |
AU4010395A (en) * | 1994-10-27 | 1996-05-23 | Amgen, Inc. | Compositions for increased bioavailability of orally delivered therapeutic agents |
JPH10513350A (ja) * | 1995-01-31 | 1998-12-22 | ザ ロックフェラー ユニヴァーシティ | DEC(樹状細胞及び上皮細胞、205 kDa)の同定、C型レクチンドメインを有するレセプター、DECをコードする核酸、及びこれらの使用 |
WO1997007128A1 (en) * | 1995-08-21 | 1997-02-27 | Duke University | A method to increase the density of antigen on antigen presenting cells |
SK40198A3 (en) * | 1995-09-28 | 1998-11-04 | Univ Pittsburgh | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
US6489145B1 (en) * | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
WO1997032987A1 (en) * | 1996-03-08 | 1997-09-12 | University Of Toronto | Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization |
US6096548A (en) * | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
-
1999
- 1999-02-10 AU AU32910/99A patent/AU3291099A/en not_active Abandoned
- 1999-02-10 MX MXPA00007891A patent/MXPA00007891A/es unknown
- 1999-02-10 WO PCT/US1999/003022 patent/WO1999041369A2/en not_active Application Discontinuation
- 1999-02-10 JP JP2000531550A patent/JP2002503461A/ja not_active Withdrawn
- 1999-02-10 EP EP99906948A patent/EP1053312A2/en not_active Withdrawn
- 1999-02-10 JP JP2000531583A patent/JP2002503478A/ja not_active Withdrawn
- 1999-02-10 CA CA002320431A patent/CA2320431A1/en not_active Abandoned
- 1999-02-10 AU AU26741/99A patent/AU2674199A/en not_active Abandoned
- 1999-02-10 CA CA002320960A patent/CA2320960A1/en not_active Abandoned
- 1999-02-10 MX MXPA00007889A patent/MXPA00007889A/es unknown
- 1999-02-10 AU AU26742/99A patent/AU2674299A/en not_active Abandoned
- 1999-02-10 WO PCT/US1999/003023 patent/WO1999041402A2/en not_active Application Discontinuation
- 1999-02-10 WO PCT/US1999/003020 patent/WO1999041368A2/en not_active Application Discontinuation
- 1999-02-10 EP EP99932508A patent/EP1056842A2/en not_active Withdrawn
- 1999-02-10 EP EP99906949A patent/EP1053343A2/en not_active Withdrawn
- 1999-02-10 MX MXPA00007893A patent/MXPA00007893A/es unknown
- 1999-02-10 JP JP2000531549A patent/JP2002507392A/ja not_active Withdrawn
- 1999-02-10 CA CA002320626A patent/CA2320626A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999041402A2 (en) | 1999-08-19 |
JP2002503478A (ja) | 2002-02-05 |
CA2320626A1 (en) | 1999-08-19 |
MXPA00007889A (es) | 2002-09-18 |
WO1999041369A3 (en) | 1999-09-23 |
EP1053312A2 (en) | 2000-11-22 |
EP1053343A2 (en) | 2000-11-22 |
CA2320960A1 (en) | 1999-08-19 |
AU3291099A (en) | 1999-08-30 |
AU2674299A (en) | 1999-08-30 |
JP2002507392A (ja) | 2002-03-12 |
MXPA00007893A (es) | 2002-10-23 |
WO1999041402A3 (en) | 1999-11-11 |
MXPA00007891A (es) | 2002-09-18 |
AU2674199A (en) | 1999-08-30 |
JP2002503461A (ja) | 2002-02-05 |
EP1056842A2 (en) | 2000-12-06 |
WO1999041368A3 (en) | 1999-12-16 |
WO1999041368A2 (en) | 1999-08-19 |
WO1999041369A2 (en) | 1999-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2320431A1 (en) | Targeting of genetic vaccine vectors | |
US20080019988A1 (en) | Targeting of genetic vaccine vectors | |
CA2325351C (en) | Non-stochastic generation of genetic vaccines and enzymes | |
JP7370861B2 (ja) | Hlaに基づく方法および組成物ならびにそれらの使用 | |
US20070087373A1 (en) | Optimization of immunomodulatory properties of genetic vaccines | |
US20010006950A1 (en) | Genetic vaccine vector engineering | |
US20090130718A1 (en) | Gene site saturation mutagenesis | |
JP2002507393A (ja) | 抗原ライブラリー免疫 | |
US8754015B2 (en) | Modified phage for displaying post-translationally modified proteins and uses thereof | |
EP1699481A2 (en) | Methods and compositions comprising bacteriophage nanoparticles | |
US20020165149A1 (en) | Mutated class II major histocompatibility proteins | |
AU2767702A (en) | Targeting of genetic vaccine vectors | |
US20030036506A1 (en) | Mutated class I major histocompatibility proteins and complexes | |
CA2492661C (en) | Non-stochastic generation of genetic vaccines and enzymes | |
EP1518927A2 (en) | Optimization of immunomodulatory properties of genetic vaccines | |
AU2757902A (en) | Genetic vaccine vector engineering | |
AU2761302A (en) | Optimization of immunomodulatory properties of genetic vaccines | |
CN114703229A (zh) | 一种基于人源细胞的表面展示技术及靶向hbv受体的多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |